Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC) - 11/18/2021 - 11/19/2021
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) and Center for Drug Evaluation and Research (CDER) welcome you to this FDA Virtual Public Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Two tablet a day treatment that can stop bladder cancer for 18 months
Professor Thomas Powels, pictured, oncologist and director of the Barts Cancer Centre where the trial took place said those given the two-pronged treatment will 'undoubtedly live for longer'. (Source: the Mail online | Health)
Source: the Mail online | Health - September 18, 2021 Category: Consumer Health News Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

DR ELLIE CANNON: I can't stop worrying that cancer runs in my family - and I'll be next
Cancer isn't one disease, it's many. So, for example, the causes and characteristics of bladder cancer are quite distinct and not connected to those of stomach cancer or other cancers, says DR ELLIE. (Source: the Mail online | Health)
Source: the Mail online | Health - September 4, 2021 Category: Consumer Health News Source Type: news

Accelerated Approval Now Full for Pembro in Bladder Cancer Accelerated Approval Now Full for Pembro in Bladder Cancer
A controversial accelerated approval of this immunotherapy, based on response data, has now been converted to a full approval by the FDA.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

What Are the First Signs of Bladder Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 31, 2021 Category: General Medicine Source Type: news

Researchers Study New Immunotherapy Combination for Mesothelioma
The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural mesothelioma, according to a recent study. Its effectiveness, comparable to a similar combination which was approved in 2020 by the U.S. Food and Drug Administration, further illustrated the new direction for future treatment of mesothelioma. Chemotherapy will no longer be the stand-alone, standard-of-care treatment for most patients. “Promising results have emerged on the use of targeted treatment with immune checkpoint inhibitors (ICI), particu...
Source: Asbestos and Mesothelioma News - August 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Nivolumab Gets Additional Adjuvant Indication for Bladder Cancer Nivolumab Gets Additional Adjuvant Indication for Bladder Cancer
A potential new standard of care?FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 23, 2021 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Alert Source Type: news

English may miss out on new drug for bladder cancer
Married father-of-two Guy Heath (pictured) was told he could have just weeks to live, but after taking avelumab he feels he is now getting back to his old self. (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2021 Category: Consumer Health News Source Type: news

Bladder cancer: The uncomfortable pain indicating your risk to the deadly disease
BLADDER cancer: When bladder tumours grow larger, or cancer cells spread to other areas of the body, they may cause symptoms including an inability to urinate or weakness and fatigue. Pain felt on a certain body part may also indicate your risk. (Source: Daily Express - Health)
Source: Daily Express - Health - August 12, 2021 Category: Consumer Health News Source Type: news

Women voice frustration over current care for recurrent urinary tract infections
This study really gave us insight into the patient perspective and showed us those with recurrent UTIs are dissatisfied with the current management of the condition. Continued episodes can have a major impact on their quality of life.”More than half of women will develop a UTI at some point, and roughly 1 in 4 will have repeat infections that can last for years. Many with recurrent infections will be prescribed antibiotics frequently over their lifetime.The researchers conducted focus groups with 29 women with recurrent UTIs — defined as two infections in six months or three in a year. Participants were asked a...
Source: UCLA Newsroom: Health Sciences - August 4, 2021 Category: Universities & Medical Training Source Type: news

FDA Grants Orphan Drug Designation to Novel Mesothelioma Treatment
The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step toward another potential therapy option for patients. ONCOFID-P is an innovative drug conjugate already in advanced clinical development for the treatment of invasive bladder cancer. The mesothelioma designation is based on preclinical data showing high antitumor activity in laboratory and mice models. Fidia Farmaceutici, a multinational research company based in Italy, announced the latest FDA designation, which is designed to encourage the development of novel drugs, par...
Source: Asbestos and Mesothelioma News - July 28, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger researchers and colleagues report a study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy in a manner that is similar to patients without that mutation. This discovery runs counter to previous research that suggested FGFR3-mutated bladder cancers should not be treated with immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Undone Proteins Take Out Bladder Cancer
An unfolded protein found in human milk shows promise in early clinical trials to treat bladder cancer. (Source: The Scientist)
Source: The Scientist - July 20, 2021 Category: Science Tags: Sponsored Article Source Type: news

First in Human Procedure with Vessi Medical's Cryotherapy System for Bladder Cancer
MISGAV, Israel, July 14, 2021 -- (Healthcare Sales & Marketing Network) -- Vessi Medical ("Vessi"), announced that it successfully completed a first-in-human case with its minimally invasive cryoablation solution for superficial bladder cancer ... Devices, Urology, Oncology Vessi Medical, cryoablation, bladder cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 14, 2021 Category: Pharmaceuticals Source Type: news

Cancer symptoms: Seven common warning signs of a growing tumour in the prostate
CANCEROUS cells that are pushing up against the urethra - the tube that carries urine from the bladder out through the tip of the penis - will cause bodily sensations. (Source: Daily Express - Health)
Source: Daily Express - Health - July 11, 2021 Category: Consumer Health News Source Type: news

Oncotarget: Urine RNA reveal tumor markers for human bladder cancer
(Impact Journals LLC) This Oncotarget work strongly suggests exploiting urine RNAs as diagnostic markers of bladder cancer and it suggests specific novel markers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2021 Category: Cancer & Oncology Source Type: news

Carbogen and Nicotinamide With Radiation Feasible for Bladder Cancer
THURSDAY, July 8, 2021 -- The use of concurrent carbogen and nicotinamide (CON) with radiation therapy is feasible for patients with muscle invasive bladder cancer (MIBC) in the Australian setting, according to a study published online June 30 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 8, 2021 Category: Pharmaceuticals Source Type: news

Nicotine by-product can predict recurrence of cancer
(European Association of Urology) A by-product of nicotine, found in the urine of smokers, could be used to identify when bladder cancer has returned, new research has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: news

Aging-related conditions increase treatment burden in older cancer patients
(Geisinger Health System) Having multiple chronic health conditions and living in a rural area were the top two factors affecting increased healthcare system contact among older patients with bladder cancer, a research team has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

New model aims to promote better-adapted bladder cancer treatment in the future
(Uppsala University) Uppsala University scientists have designed a new mouse model that facilitates study of factors contributing to the progression of human bladder cancer and of immune-system activation when the tumour is growing. Using this model, they have been able to study how proteins change before, while and after a tumour develops in the bladder wall. The study has now been published in the scientific journal PLOS ONE. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

New approach todrug design yields highly promising bladder cancer drug candidate
(Trinity College Dublin) A new approach to molecular drug design has yielded a highly promising bladder cancer drug, which induced rapid shedding of tumour cells and resulted in a significant reduction in tumour size when used in clinical trials. These potent effects were seen in patients with non-muscle invasive bladder cancer (NMIBC) and the treatment was shown to be safe, as no drug-related side effects were observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Study suggests blood test could guide precision treatment in bladder cancer
(Queen Mary University of London) A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led by Professor Tom Powles from Queen Mary University of London and Barts Health NHS Trust. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 21, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: Toilet troubles that are indicative of a growing tumour in the bladder
CANCER cells can amass into a tumour along the bladder lining, and in some cases, it can spread into the muscle. When cancer is present in that area of the body, toilet troubles start to emerge. Do you know what to look out for? (Source: Daily Express - Health)
Source: Daily Express - Health - June 12, 2021 Category: Consumer Health News Source Type: news

How to Avoid Cystectomy in Muscle-Invasive Bladder Cancer How to Avoid Cystectomy in Muscle-Invasive Bladder Cancer
Nearly half the patients with muscle-invasive bladder cancer had clinical complete responses, showing that bladder-intact recurrence-free survival is possible.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO: Bladder Sparing Studied in Muscle - Invasive Bladder Cancer
Transurethral resection then gemcitabine, cisplatin, plus nivolumab with intact bladder in selected patients studied in phase 2 trial (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 7, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Urology, Conference News, Source Type: news

Can You Keep Your Bladder After Bladder Cancer Strikes?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 7, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Surgery, News, Source Type: news

ASCO: Bladder Sparing Studied in Muscle-Invasive Bladder Cancer
MONDAY, June 7, 2021 -- For patients with muscle-invasive bladder cancer, transurethral resection and combination treatment with gemcitabine, cisplatin, plus nivolumab with bladder sparing is feasible in selected patients, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 7, 2021 Category: Pharmaceuticals Source Type: news

Can You Keep Your Bladder After Bladder Cancer Strikes?
MONDAY, June 7, 2021 -- After being diagnosed with bladder cancer, some patients face an almost impossible decision -- have their bladder removed or take a risk knowing that the cancer may be more likely to spread if the bladder is left intact. But... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 7, 2021 Category: General Medicine Source Type: news

Can You Keep Your Bladder After Bladder Cancer Strikes?
Title: Can You Keep Your Bladder After Bladder Cancer Strikes?Category: Health NewsCreated: 6/7/2021 12:00:00 AMLast Editorial Review: 6/7/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 7, 2021 Category: Cancer & Oncology Source Type: news

Study shows novel test can detect new and recurrent bladder cancer
Detection of bladder cancer is often difficult and expensive, but this non-invasive urine screening test could make a significant positive impact. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 4, 2021 Category: Universities & Medical Training Source Type: news

Immunotherapy after bladder cancer surgery may reduce recurrence, study shows
(Memorial Sloan Kettering Cancer Center) ew research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo ® ) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in theNew England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning in a deadly metastatic form, according to results published in The New England Journal of Medicine. The immunotherapy nivolumab was used as an adjuvant therapy, which is given after surgery in the hopes of maximizing its effectiveness. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Finding new cost-effective treatment options for BCG-unresponsive bladder cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Progression in high-risk non-muscle invasive bladder cancer
(Impact Journals LLC) This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: Toilet troubles may be indicative of a growing tumour – signs
CANCER can influence how you use the toilet. A growing tumour - depending on where it is - can cause difficulties when it comes to emptying the bowels and bladder. Here are the warning signs to take note of. (Source: Daily Express - Health)
Source: Daily Express - Health - May 30, 2021 Category: Consumer Health News Source Type: news

Oncotarget: Urine protein biomarkers of bladder cancer
(Impact Journals LLC) These Oncotarget findings suggest that urine IL-1α, IL-1ra and IL-8 are useful indicators of bladder cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic Q & amp;A podcast: Bladder cancer patients require ongoing surveillance
Bladder cancer is a common type of cancer that begins in the cells of the bladder, a hollow muscular organ in the lower abdomen that stores urine. Bladder cancer signs and symptoms can include blood in the urine, frequent or painful urination, and back pain. "The vast majority of bladder cancer patients are diagnosed with cancer that's not [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 17, 2021 Category: Databases & Libraries Source Type: news

Consumer Health: Bladder cancer awareness
May is Bladder Cancer Awareness Month, which makes this a good time to learn more about bladder cancer. Bladder cancer is one of the most common cancers. Nearly 84,000 new cases will be diagnosed in the U.S. in 2021, according to the American Cancer Society. Bladder cancer occurs in men more frequently than in women, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 13, 2021 Category: Databases & Libraries Source Type: news

How Long Will You Live if You Have Bladder Cancer?
Title: How Long Will You Live if You Have Bladder Cancer?Category: Diseases and ConditionsCreated: 5/6/2021 12:00:00 AMLast Editorial Review: 5/6/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 6, 2021 Category: Cancer & Oncology Source Type: news

What Are the Different Stages of Bladder Cancer?
Title: What Are the Different Stages of Bladder Cancer?Category: Diseases and ConditionsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 30, 2021 Category: Cancer & Oncology Source Type: news

To Stay: Two More Cancer Indications With'Dangling Approvals'To Stay: Two More Cancer Indications With'Dangling Approvals '
On the second day of a historic meeting, FDA advisers voted to keep the accelerated approvals for two immunotherapies for use in bladder cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for previously untreated metastatic bladder cancer
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothel ial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumours express high levels of PD-L1 (PD-L1–stained tumour-infiltrating immune cells covering ≥5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for ...
Source: Roche Investor Update - April 28, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for previously untreated metastatic bladder cancer
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothel ial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumours express high levels of PD-L1 (PD-L1–stained tumour-infiltrating immune cells covering ≥5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for ...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Male bladder cancer vulnerability could lead to a new treatment approach
(University of California - Davis Health) UC Davis Comprehensive Cancer Center researchers found that targeting androgen receptors - a type of protein that is crucial for the function of testosterone - may destroy cancer cells. Focusing on this protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer in men. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2021 Category: International Medicine & Public Health Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news